Table 4.
Comparison of miR-155 expression among clinical categories.
| Pathological categories | Sample size | x-fold expression ± SD (vs. control) | p (ANOVAǂ) | p (vs. control) (Tukeyᵻ) |
|---|---|---|---|---|
| Normal | 36 | 1 ± 0.33 | ||
| Histology grade | ||||
| WD | 10 | 1.38 ± 0.3 | <0.001 | 0.016 |
| MD | 15 | 1.67 ± 0.52 | <0.001 | |
| PD | 11 | 2.07 ± 0.81 | <0.001 | |
|
| ||||
| TNM stage | ||||
| Stage I | 8 | 1.53 ± 0.5 | <0.001 | 0.002 |
| Stage II | 17 | 1.62 ± 0.38 | <0.001 | |
| Stage III | 11 | 1.91 ± 0.94 | <0.001 | |
|
| ||||
| Tumor size (T) | ||||
| T1 (T < 2) | 11 | 1.48 ± 0.45 | <0.001 | 0.0015 |
| T2 (2 ≤ T < 5) | 18 | 1.75 ± 0.47 | <0.001 | |
| T3 (T ≥ 5) | 7 | 1.87 ± 1.08 | <0.001 | |
|
| ||||
| Lymph node involvement (N) | ||||
| Yes | 17 | 1.86 ± 0.82 | 0.15 | <0.001 |
| No | 19 | 1.54 ± 0.37 | <0.001 | |
|
| ||||
| Estrogen receptor (ER) | ||||
| ER+ | 24 | 1.65 ± 0.73 | 0.84 | <0.001 |
| ER- | 12 | 1.75 ± 0.49 | <0.001 | |
|
| ||||
| Progesterone receptor (PR) | ||||
| PR+ | 19 | 1.77 ± 0.81 | 0.54 | <0.001 |
| PR- | 17 | 1.60 ± 0.38 | <0.001 | |
|
| ||||
| HER2 | ||||
| HER+ | 9 | 1.78 ± 0.66 | 0.79 | <0.001 |
| HER- | 27 | 1.65 ± 0.65 | <0.001 | |
|
| ||||
| Ki-67 | ||||
| ≤10% | 14 | 1.64 ± 0.56 | 0.9 | <0.001 |
| >10% | 22 | 1.71 ± 0.71 | <0.001 | |
WD = grade 1; MD = grade 2; PD = grade 3; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2. ǂThe analysis of variance (ANOVA) was performed for the analysis. ᵻTukey multiple comparison.